Danaher Corporation. (3/31/20). "Press Release: Danaher Completes Acquisition Of The Biopharma Business Of General Electric Life Sciences, Business Will Be Called Cytiva". Washington, DC.

	Organisation	Danaher Corporation (NYSE: DHR)
	Group	Danaher (Group)
	Organisation 2	GE Biopharma
	Today	Cytiva (formerly GE Biopharma business of GE Life Sciences)
	Group	Danaher (Group)
	Product	LIFE SCIENCES
	Product 2	laboratory equipment and instruments
	Index term	General Electric–Danaher: investment, 201902–202003 acquisition $21.4b in cash of biopharma business of GE Life Sciences
	Person	Gugino, Matthew E. (Danaher 201407 VP Investor Relations)

Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of the Biopharma business from General Electric Company's (NYSE: GE) Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a standalone operating company within Danaher's Life Sciences segment.

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.

For further information:

Matthew E. Gugino, Vice President, Investor Relations, Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850, Fax: (202) 828-0860; MEDIA CONTACT: George Sard, Sard Verbinnen & Co, Telephone: (212) 687-8080, Email: gsard@sardverb.com

Record changed: 2020-04-01